Vassiliki Papadimitrakopoulou named clinical development leader of Pfizer Oncology

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Vassiliki Papadimitrakopoulou was named clinical development leader of Pfizer Oncology and will join Pfizer Sept. 23.

Papadimitrakopoulou specializes in personalized genomics-driven cancer therapies, immunotherapies, translational research and cancer chemoprevention. She comes to Pfizer from MD Anderson Cancer Center, where she was professor of medicine in the Department of Thoracic/Head and Neck Medical Oncology. There, she led clinical and translational research projects focused on the development of biomarker-based targeted therapies to overcome therapeutic resistance in advanced disease.

Papadimitrakopoulou was recently a member of the FDA Oncologic Drugs Advisory Committee and has served as co-principal investigator on the Master Lung Protocol (Lung-MAP) study, an umbrella trial simultaneously testing multiple precision medicines in squamous cell lung cancer, supported by NCI and run through patient advocacy organizations, pharmaceutical companies (including Pfizer) and public institutions.

Table of Contents

YOU MAY BE INTERESTED IN

After reading “Breast Cancer Mortality Continues Three-Decade Decline, but Steeper Increases for Women Under 50 & AAPI Women of All Ages,” it is evident that while overall progress is being made in the fight against cancer, concerning disparities remain—particularly within the Native Hawaiian and Pacific Islander (NHPI) communities. 

Login